| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Evercore ISI Group analyst Elizabeth Anderson maintains CVS Health (NYSE:CVS) with a Outperform and raises the price target ...
RBC Capital analyst Ben Hendrix maintains CVS Health (NYSE:CVS) with a Outperform and raises the price target from $81 to $93.
Cantor Fitzgerald analyst Sarah James maintains CVS Health (NYSE:CVS) with a Overweight and raises the price target from $78...
Truist Securities analyst David Macdonald reiterates CVS Health (NYSE:CVS) with a Buy and raises the price target from $92 t...
A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelle...
CVS Health topped Q3 estimates with $102.9 billion in revenue and raised its 2025 EPS outlook to up to $6.65 amid strong segmen...
CVS Health (NYSE:CVS) lowers FY2025 GAAP EPS guidance from $3.84-$3.94 to $(0.34)-$(0.24) vs $3.96 analyst estimate..